A Phase 3 interventional study of Peginterferon alfa-2b (PegIFN-2b) and Comparator: Stronger neo minophagen C (SNMC) in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 10th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 22 in phase 3, and was the 21st registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 99 across the 39 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 20th largest by enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2006, is one of 32 in phase 3, and was the 23rd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to compare the efficacy of peginterferon alfa-2b (PegIFN-2b) monotherapy administered at a dose of 0.5 ug/kg vs stronger neo minophagen C (SNMC) in participants with chronic hepatitis C (CHC) and liver fibrosis (Metavir fibrosis score of F2 and F3) who were previously treated with interferon. The trial will evaluate the effect of treatment on the progression of liver fibrosis, liver inflammation, and liver function. Treatment will be administered for up to 156 weeks with a 4-week follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet the following laboratory criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
Biological: Peginterferon alfa-2b (PegIFN-2b)
Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
Drug: Comparator: Stronger neo minophagen C (SNMC)
PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
Also known as: SCH 054031, Pegylated interferon alfa-2b
SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
Number of Participants With Change in Metavir Fibrosis Score
Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).
Time frame: Baseline and discontinuation of treatment (up to 156 weeks)
Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration
The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.
Time frame: Week 24
Number of Participants With Change in Metavir Inflammation Score
Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).
Time frame: Baseline and Week 48
| Milestone | PegIFN-2b | SNMC |
|---|---|---|
| Started | 127 | 134 |
| Completed | 45 | 53 |
| Not completed | 82 | 81 |
| Withdrew: Withdrawal by subject | 11 | 18 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Treatment-related adverse event | 10 | 9 |
| Withdrew: Met discontinuation criteria | 5 | 0 |
| Withdrew: Onset of malignant tumor | 11 | 11 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Circumstances of site | 1 | 1 |
| Withdrew: Did not meet protocol eligibility | 1 | 0 |
| Withdrew: Irregular visits | 1 | 0 |
| Withdrew: Study discontinuation | 35 | 32 |
| Withdrew: Never received study drug | 2 | 6 |
Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).
| Participants | PegIFN-2b | SNMC |
|---|---|---|
| Participants with ≥1grade lower score (improved) | 13 | 11 |
| Participants with no change in score | 79 | 79 |
| Participants with ≥1 grade higher score (worsened) | 31 | 36 |
The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.
| Participants | PegIFN-2b | SNMC |
|---|---|---|
| Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration | 9 | 2 |
Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).
| Participants | PegIFN-2b | SNMC |
|---|---|---|
| Participants with ≥1grade lower score (improved) | 48 | 23 |
| Participants with no change in score | 55 | 61 |
| Participants with ≥1grade higher score (worsened) | 19 | 42 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PegIFN-2b | — | 32/125 (25.6%) | 125/125 (100%) |
| SNMC | — | 23/127 (18.1%) | 123/127 (96.9%) |
| Event | PegIFN-2b | SNMC |
|---|---|---|
| HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/125 | 10/127 |
| DEAFNESS NEUROSENSORYEar and labyrinth disorders | 1/125 | 0/127 |
| MENIERE'S DISEASEEar and labyrinth disorders | 1/125 | 0/127 |
| DUODENAL ULCERGastrointestinal disorders | 1/125 | 0/127 |
| GINGIVAL BLEEDINGGastrointestinal disorders | 1/125 | 0/127 |
| PANCREATITISGastrointestinal disorders | 1/125 | 0/127 |
| PANCREATITIS ACUTEGastrointestinal disorders | 1/125 | 0/127 |
| VARICES OESOPHAGEALGastrointestinal disorders | 1/125 | 0/127 |
| PYREXIAGeneral disorders | 1/125 | 0/127 |
| APPENDICITISInfections and infestations | 1/125 | 0/127 |
| Event | PegIFN-2b | SNMC |
|---|---|---|
| MALAISEGeneral disorders | 97/125 | 51/127 |
| PYREXIAGeneral disorders | 87/125 | 25/127 |
| HEADACHENervous system disorders | 82/125 | 42/127 |
| LYMPHOCYTE COUNT DECREASEDInvestigations | 80/125 | 45/127 |
| NASOPHARYNGITISInfections and infestations | 77/125 | 81/127 |
| PLATELET COUNT DECREASEDInvestigations | 74/125 | 19/127 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 72/125 | 31/127 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 68/125 | 9/127 |
| MYALGIAMusculoskeletal and connective tissue disorders | 68/125 | 24/127 |
| HYALURONIC ACID INCREASEDInvestigations | 62/125 | 46/127 |
| Age, Continuous(years) | PegIFN-2b | SNMC | Total |
|---|---|---|---|
| Mean | 59.8 ± 9.5 | 60.7 ± 8.9 | 60.3 ± 9.2 |
| Sex: Female, Male(Participants) | PegIFN-2b | SNMC | Total |
|---|---|---|---|
| Female | 60 | 65 | 125 |
| Male | 65 | 62 | 127 |
| Region of Enrollment(participants) | PegIFN-2b | SNMC | Total |
|---|---|---|---|
| Japan | 125 | 127 | 252 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Dec 2006, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b